Global Erythropoietin Drugs Market to Reach US$ 17.3 Billion by 2032, Bolstered by Rising Prevalence of Anemia

December 05, 2022 | Healthcare

According to the latest report by IMARC Group, titled “Erythropoietin Drugs Market Report by Drug Class (Biologics, Biosimilars), Product Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, and Others), Application (Hematology, Kidney Disorder, Cancer, and Others), End-User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2024-2032," the global erythropoietin drugs market size reached US$ 11.0 Billion in 2023. Erythropoietin (EPO) is a hormone produced naturally by kidneys to stimulate the production of red blood cells (RBCs) in the body. Its deficiency or excess leads to severe medical conditions, such as low hemoglobin levels and kidney diseases. EPO drugs, also known as haematopoietin, are injectable drugs used to cure anemia and increase RBC production. They are widely used to treat anemic conditions caused by chronic renal disease, cancer treatment, myelodysplasia, medicine side effects, and surgery. They also help reduce infections in acquired immune deficiency syndrome (AIDS) and pre-operative blood transfusion. EPO drugs mimic the naturally occurring erythropoietin and stimulate the bone marrow to produce more RBCs. 

Global Erythropoietin Drugs Market Trends:

The widespread prevalence of chronic diseases, such as cancer, AIDS, and kidney problems, is one of the primary factors driving the market growth. EPO drugs are widely used to treat anemic conditions induced by end-stage renal disease (ESRD), antiretroviral treatments (ART), chemotherapy, radiotherapy, and other cancer treatments. In addition to this, rising product utilization to treat critically ill patients owing to its anti-ischemic, anti-apoptotic, and regenerative effects in various tissues, such as lungs, kidneys, nervous system, pancreas, and retina, is acting as another growth-inducing factor. Furthermore, the rapid commercialization of highly efficient biosimilars, which are easy to switch, cost-effective, and require less approval time, is providing an impetus to the market growth. In line with this, the widespread product application in chemotherapy cycles, along with the increasing incidences of end-stage renal diseases (dialysis), is favoring the market growth. Additionally, the recent repurposing of EPO drugs for treating diabetes mellitus (DM) due to its cytoprotective effect that enhances cardiac function, reduces fatigue, and improves cognition in DM patients is positively influencing the market growth. Moreover, the implementation of various government initiatives to incentivize research on chronic diseases through grants, drug exclusivity, fee waivers, and tax credits is propelling the market growth. Other factors, including rising awareness regarding the benefits of EPO therapeutics, the increasing geriatric population in need of surgical procedures, and rising strategic collaborations among drug manufacturers due to high return on investment (ROI), are anticipated to drive the market growth. On account of the aforementioned factors, the market value is expected to reach US$ 17.3 Billion by 2032, exhibiting a CAGR of 5% during 2024-2032.

Market Summary:

  • On the basis of drug class, the market has been bifurcated into biologics and biosimilars.
  • Based on the product type, the market has been classified into epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others.
  • On the basis of the application, the market has been divided into hematology, kidney disorder, cancer, and others.
  • Based on the end user, the market has been classified hospitals, homecare, specialty clinics, and others.
  • On a regional basis, the market has been categorized into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and Others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and Others), Latin America (Brazil, Mexico, and Others), and Middle East and Africa.
  • The competitive landscape of the industry has also been examined, with some of the key players being Amgen Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Ltd.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Drug Class, Product Type, Application, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Amgen Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Ltd.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

30 N Gould St, Ste 
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Erythropoietin Drugs Market to Reach US$ 17.3 Billion by 2032, Bolstered by Rising Prevalence of Anemia
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More